Jing Yan

The project will investigate genomic features in DVG and DI formation in #enteroviruses using #molecular biology and #bioinformatics. PhD Student in Virology/Bionformatics Otto von Guericke Universität Magdeburg See the full job description on jobRxiv: https://lnkd.in/dAZwFw9B #bioinformatics #RNAseq #virology

8

The official statement of the Postdoc Networks of Germany regarding the 4+2 update to the #WissZeitVG was released today. Thank you to the Max Plank PostdocNet for leading this effort and to all the postdocs who participated in discussions and editing. "In our opinion, the problems that we and other status groups at German academic institutions have pointed out are fundamentally incompatible with the stated objectives of the proposed changes in the amendment. These objectives include "good and competitive employment and career conditions", a "cultural change in science", attractive "working conditions at universities and research institutions" as "an essential key to maintaining and expanding Germany's international competitiveness and innovative capacity", "reliability, predictability and transparency for scientists in early career phases" and "a better work-life balance" (Gesetzesentwurf der Bundesregierung, Entwurf eines Gesetzes zur Änderung des Befristungsrechts für die Wissenschaft, p. 1). Due to the incompatibility of the problems identified and the objectives set out in the amendment, we strongly oppose the amendment, both as postdoctoral researchers and as citizens and international researchers of Germany."

17

New PANCAID review hot off the digital press! Kim-Lea Reese, Prof. Klaus Pantel, and Dr. Dr. Daniel J. Smit from Universitätsklinikum Hamburg Eppendorf just published a narrative review, where they present an overview of different #liquidbiopsy biomarkers for the early diagnosis of Pancreatic ductal adenocarcinoma (PDAC) and discuss the validity of multimarker panels. Read the full article here (it’s #OpenAccess) 🔓 https://lnkd.in/dPdWy2ns This review is part of PANCAID’s #workpackage 2! #PancreaticCancer #cancerresearch #oncology

21

👏 Congratulations, Oren Moscovitz! Fantastic News from the Max Planck Institute of Colloids and Interfaces: Oren Moscovitz receives Hermann Neuhaus Prize (https://lnkd.in/dmy-Rms2) of the Max Planck Society for his cancer research on non-invasive diagnostics! Dr. Oren Moscovitz has been awarded €25,000 by the Max Planck Society for his promising research toward treatments and non-invasive diagnostics for cancer, which could potentially reduce overall cancer-related deaths. Moscovitz and his team exploit unique sugar patterns found on cancer cells and develop ultra-small antibodies from alpacas (known as nanobodies) that bind to these sugars. Two start-ups are already working to bring these findings closer to public fruition. Read more in the link below! #MaxPlanckResearch #glycobiology #cancerresearch #antibodies #PotsdamSciencePark #LifeSciences Max-Planck-Institut für Kolloid- und Grenzflächenforschung

7

📢 The official website of the Molecular Neuro-Pathology Outreach Consortium is Now Live! 🎉 Our team at the Hopp Children's Cancer Center (#KiTZ), DKFZ German Cancer Research Center, University Hospital Heidelberg (UKHD) is at the forefront of revolutionizing diagnostics of CNS tumor and sarcoma through methylation-based classification; a method we innovated that now informs WHO diagnostic standards. Our mission at the #MNP_Outreach_Consortium is to facilitate the global uptake of this technology, particularly in low-to-middle-income countries (LMICs) where cost and access pose significant barriers. We also intend to fill significant biological knowledge gaps in populations from the global South.  On our website, you can explore: 🌟  The pillars of our scientific program, which covers cutting-edge molecular methodologies for methylation-based tumor classification, AI prediction of methylation classes from pathology H&E slides and Generating multiomic data about tumors enriched in partner countries. 🧬 A dynamic rich global data repository serving as a foundational resource to fill critical gaps in genomic databases related to previously unexplored populations. 📚 Training and educational resources for partner institutions, and you can stay updated with announcements about upcoming events and training workshops. 🗓 Monthly international tumor board in collaboration with Washington University in St. Louis, Mohamed Abdelbaki, Lorena Baroni, where you can stay connected with our global scientific network and get expert consultation about CNS tumor patients. 💝 If you like our work, you can join us making a difference and offering hope to cancer patients in LMICs🌍🕊, by supporting our program. 📢 You can also stay updated by following our X page: #@MnpOutreach 👌 🙏 Big thanks to our supporters: Illumina, BILD hilft e.V. „Ein Herz für Kinder", Heidelberg Epignostix GmbH and Sidra Medicine, and all partners 🤝 King Hussein Cancer Foundation and Center, Amal Al Omari, Maysa Al Hussaini, Sidra Medicine, Wouter Hendrickx, AGA KHAN UNIVERSITY, Syed Ather Enam, Ahmed Gilani, Clinical Research Center (CRC) at CCHE 57357, Shahenda EL-Naggar, TATA MEDICAL CENTER, Sushant Vinarkar, rimpa basu, Paromita Roy, All India Institute of Medical Sciences, Vaishali suri, Dr. Felipe D'Almeida Costa, MD, PhD, A.C.Camargo Cancer Center, USP - Universidade de São Paulo, Leslie Kulikowski, Dasa, Cristovam Scapulatempo Neto, Universitas Indonesia Hospital, Ludi Dhyani Rahmartani, Mahidol University, Thidathip Wongsurawat, Sith Sathornsumetee, Fleni, Horacio Martinetto, UC CHRISTUS, Pablo Zoroquiain. https://mnpoutreach.com/

54

9 Kommentare

New paper alert! A collaboration between scientists in the labs of Julius Brennecke and Ulrich Elling at IMBA, Alex Stark at Research Institute of Molecular Pathology (IMP) and Stefan L Ameres at the Max Perutz Labs Vienna has resulted in the development of a novel system for protein mass tagging, called ORFtag. The new system allows researchers to systematically study protein function. By leveraging a retrovirus—a type of virus that can sneak its genetic material into the DNA of the cells it infects—, ORFtag inserts a small piece of DNA at millions of random positions in the target cell's genome. This DNA produces a "tag" that attaches to newly made proteins, making it possible to identify and study them in large-scale parallel assays. ORFtag enables researchers to efficiently and affordably explore the roles of nearly all proteins in a cell, opening up new possibilities for studying cellular functions and disease mechanisms. This discovery represents a great example of the collaborative nature of science done at the Vienna BioCenter, where scientists from different institutes contribute their expertise to ground-breaking research. ➡ More information: https://bit.ly/ORFtag

38

𝗖𝗼𝗺𝗽𝗮𝗰𝘁 “𝗴𝗲𝗻𝗲 𝘀𝗰𝗶𝘀𝘀𝗼𝗿” 𝗲𝗻𝗮𝗯𝗹𝗲𝘀 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲 𝗴𝗲𝗻𝗼𝗺𝗲 𝗲𝗱𝗶𝘁𝗶𝗻𝗴: CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known “gene scissor” but is much smaller and thus easier to transport into cells. Using protein engineering and AI algorithms, UZH researchers have now enhanced TnpB capabilities to make DNA editing more efficient and versatile, paving the way for treating a genetic defect for high cholesterol in the future. 𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://lnkd.in/eK5dgv4C Gerald Schwank, Universität Zürich (UZH), ETH Zürich

2

#Health | 𝗡𝗮𝗻𝗼𝗽𝗮𝗿𝘁𝗶𝗰𝗹𝗲𝘀 𝗣𝗼𝘀𝗲 𝗮 𝗥𝗶𝘀𝗸 𝘁𝗼 𝗣𝗿𝗲𝗴𝗻𝗮𝗻𝗰𝘆 | An interdisciplinary team led by researchers at Empa has made a significant breakthrough in understanding the risks of nanoparticles on pregnancy. Collaborating with clinical partners from the Cantonal Hospital of St. Gallen and research partners from the University of Geneva, the Amsterdam University Medical Center, and the Leibniz Institute for Environmental Medical Research in Düsseldorf, the team discovered that certain nanoparticles impair the release of chemical messengers in the placenta, affecting blood vessel formation. This research was conducted using fully functional human placentas obtained after planned caesarian sections. The findings are crucial as they highlight the long-range effects of nanoparticles and their potential harm to embryonic development. The experiments revealed that nanoparticles in placental tissue disrupt the production of a large number of substances, marking a significant advancement in our understanding of nanoparticle toxicity and its implications for reproductive health. 👉 Learn more >> https://lnkd.in/g6GFbBSG 👉 Original publication >> https://lnkd.in/euHCVhtd Image: Adobe Stock 🇨🇭 Follow #ScienceSwitzerland for the latest news and emerging trends on Swiss science, technology, education, and innovation >> www.swissinnovation.org Follow us >> Science-Switzerland #Science | #Education | #Research | #Innovation

3

🎊 Our latest paper "Peptide Dendrimers Transfecting CRISPR/Cas9 Plasmid DNA: Optimization and Mechanism" by Susanna Joelle Zamolo PhD, Elena Zakharova, Ph.D., Lise Boursinhac, Florian Hollfelder, Tamis Darbre, and Jean-Louis Reymond is now published on Chemical Biology #RSCChemBio#RSCChemBio! We optimize a peptide dendrimer transfection reagent to deliver a large CRISPR/Cas9 plasmid DNA into cells, elucidate its delivery mechanism, and demonstrate its gene editing efficiency. 👉 Read the full version: https://lnkd.in/ebcdsW9T DCBP - Department of Chemistry, Biochemistry and Pharmaceutical Sciences (University of Bern) University of Bern Reymond Group Abstract Gene editing by CRISPR/Cas9 offers great therapeutic opportunities but requires delivering large plasmid DNA (pDNA) into cells, a task for which transfection reagents are better suited than viral vectors. Here we performed a structure–activity relationship study of Z22, a D-enantiomeric, arginine containing, lipidated peptide dendrimer developed for pDNA transfection of a CRISPR/Cas9 plasmid co-expressing GFP. While all dendrimer analogs tested bound pDNA strongly and internalized their cargo into cells, D-chirality proved essential for transfection by avoiding proteolysis of the dendrimer structure required for endosome escape and possibly crossing of the nuclear envelope. Furthermore, a cysteine residue at the core of Z22 proved non-essential and was removed to yield the more active analog Z34. This dendrimer shows >83% GFP transfection efficiency in HEK cells with no detrimental effect on cell viability and promotes functional CRISPR/Cas9 mediated gene editing. It is accessible by solid-phase peptide synthesis and therefore attractive for further development.

40

4 Kommentare

Let's explore how the minor spliceosome can be utilized in breast cancer research. Universität Bern  #BreastCancer  #MinorSpliceosome #DBMRinnovativeResearchPrice

69

2 Kommentare

Second Ph.D. paper from Luke Trinity's thesis is out now -- "Tying the knot: Unraveling the intricacies of the coronavirus frameshift pseudoknot". In this study, we employed the KnotAli and Shapify algorithms to enhance our knowledge of RNA structures in coronaviruses, including SARS-CoV-2. By examining the frameshift elements in 181 coronavirus RNA sequences, we identified crucial structural transitions that could improve the targeting of antiviral therapies. This research not only deepens our understanding of RNA structure-function relationships but also propels the development of innovative treatments for those impacted by these viruses. #Virology #RNAresearch #Coronavirus #covid19 RNA Canada ARN (formerly called Canadian Consortium of RNA Researchers) University of Alberta

10

Researchers from PSI Paul Scherrer Institut, ETH Zürich and University of Geneva have revealed how drug molecules bind in a type of channel that connects neighbouring cells, changing intercellular communication. The team studied channels made from proteins called connexins, which allow small molecules and ions to be exchanged between adjacent cells. Dysfunctions of these channels has been linked to many different diseases including cardiac #arrhythmias, #epilepsy and #cancer. Using cryo-electron microscopy, the team revealed how the antimalarial drug, mefloquine, binds in the channels. As well as giving a possible explanation for well-known side effects of mefloquine, the research gives new understanding of how drug molecules act on connexins channels in general, aiding the development of connexin-targeting drugs. Full Story: https://lnkd.in/dKS7T6qh CC: Volodymyr Korkhov Image: Laura Canil #ResearchAtPSI #HealthInnovation #Neuroscience #DrugDiscovery #ResearchMatters

255

𝑻𝒉𝒆 𝑹𝒐𝒖𝒕𝒆 𝑵𝒐𝒕 𝑻𝒂𝒌𝒆𝒏 - 𝑬𝒑𝒊𝒔𝒐𝒅𝒆 11 A collaborative endeavor among ETH Zürich, Oregon Health & Science University, and Roche has led to the identification of novel #CB2R inverse agonists. These compounds display exceptional binding affinity for CB2R and remarkable selectivity over CB1R, effectively reducing potential central nervous system side effects. 𝐒𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐟𝐨𝐫 𝐬𝐞𝐥𝐞𝐜𝐭𝐢𝐯𝐞 𝐂𝐁𝟐𝐑 𝐢𝐧𝐯𝐞𝐫𝐬𝐞 𝐚𝐠𝐨𝐧𝐢𝐬𝐭𝐬: 𝐂𝐡𝐞𝐦𝐀𝐈𝐑𝐒-𝐀𝐬𝐬𝐢𝐬𝐭𝐞𝐝 𝐑𝐨𝐮𝐭𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 #ChemAIRS focuses on the synthesis of these CB2R-selective inverse agonists, which are derived from the privileged scaffold of 𝐇𝐔-𝟑𝟎𝟖, a well-known CB2R agonist. The synthetic route commences with compound 3b, which was obtained via methylation of 3,5-dimethoxyphenylacetonitrile followed by treatment with phenyl lithium (Scheme 1). In the subsequent step, ChemAIRS proposed using a 𝐺𝑟𝑖𝑔𝑛𝑎𝑟𝑑 𝑟𝑒𝑎𝑔𝑒𝑛𝑡 to introduce an alkyl side chain to the ketone 3b, yielding racemic compound 4a. The conjugated alkene 4a was selectively reduced through hole-transfer catalysis to furnish 8b, which then underwent 𝐹𝑟𝑖𝑒𝑑𝑒𝑙-𝐶𝑟𝑎𝑓𝑡𝑠 𝑎𝑙𝑙𝑦𝑙𝑎𝑡𝑖𝑜𝑛 with verbenol derivative 8a, producing intermediate 9a. Hydroazidation of the alkene with TMSN3 and subsequent phthalimide deprotection via hydrazine unveiled the target molecule. 𝐀𝐥𝐭𝐞𝐫𝐧𝐚𝐭𝐢𝐯𝐞 𝐒𝐲𝐧𝐭𝐡𝐞𝐭𝐢𝐜 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐟𝐨𝐫 𝐂𝐁𝟐𝐑 𝐈𝐧𝐯𝐞𝐫𝐬𝐞 𝐀𝐠𝐨𝐧𝐢𝐬𝐭 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 In this alternative route (Scheme 2), ChemAIRS suggested alkylating ketone 1b via reaction with iodide 1a. Introduction of the gem-dimethyl group was achieved by treatment of 2a with TiCl4 and AlMe3, affording 3a, which was then brominated and reacted with B(OMe)3 to yield arylboronic acid 7b. On the other hand, N-Boc-protected allylic amine 6a was formed under 𝑀𝑖𝑡𝑠𝑢𝑛𝑜𝑏𝑢 𝑐𝑜𝑛𝑑𝑖𝑡𝑖𝑜𝑛𝑠, and subsequent bromination yielded 7a. A 𝑆𝑢𝑧𝑢𝑘𝑖 𝑐𝑜𝑢𝑝𝑙𝑖𝑛𝑔 between 7a and arylboronic acid 7b afforded 8a. The final step of this method involved Boc deprotection to generate the target molecule, 𝑖𝑛 𝑐𝑜𝑛𝑡𝑟𝑎𝑠𝑡 𝑡𝑜 𝑝ℎ𝑡ℎ𝑎𝑙𝑖𝑚𝑖𝑑𝑒 𝑟𝑒𝑚𝑜𝑣𝑎𝑙 𝑎𝑠 𝑝𝑟𝑜𝑝𝑜𝑠𝑒𝑑 𝑖𝑛 𝑆𝑐ℎ𝑒𝑚𝑒 1. In conclusion, the development of #CB2 inverse agonists presents a promising avenue for therapeutic intervention in inflammatory and immune-related diseases. 𝑻𝒉𝒆 𝒔𝒚𝒏𝒕𝒉𝒆𝒕𝒊𝒄 𝒓𝒐𝒖𝒕𝒆𝒔 𝒉𝒊𝒈𝒉𝒍𝒊𝒈𝒉𝒕𝒆𝒅 𝒃𝒚 𝑪𝒉𝒆𝒎𝑨𝑰𝑹𝑺 𝒏𝒐𝒕 𝒐𝒏𝒍𝒚 𝒑𝒓𝒐𝒗𝒊𝒅𝒆 𝒆𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒕 𝒎𝒆𝒕𝒉𝒐𝒅𝒔 𝒇𝒐𝒓 𝒂𝒄𝒄𝒆𝒔𝒔𝒊𝒏𝒈 𝒕𝒉𝒆𝒔𝒆 𝒄𝒐𝒎𝒑𝒐𝒖𝒏𝒅𝒔 𝒃𝒖𝒕 𝒂𝒍𝒔𝒐 𝒓𝒆𝒗𝒆𝒂𝒍 𝒑𝒐𝒕𝒆𝒏𝒕𝒊𝒂𝒍 𝒑𝒊𝒕𝒇𝒂𝒍𝒍𝒔 𝒊𝒏 𝒕𝒉𝒆 𝒔𝒚𝒏𝒕𝒉𝒆𝒔𝒊𝒔, 𝒐𝒇𝒇𝒆𝒓𝒊𝒏𝒈 𝒗𝒂𝒍𝒖𝒂𝒃𝒍𝒆 𝒊𝒏𝒔𝒊𝒈𝒉𝒕𝒔 𝒇𝒐𝒓 𝒇𝒖𝒕𝒖𝒓𝒆 𝒐𝒑𝒕𝒊𝒎𝒊𝒛𝒂𝒕𝒊𝒐𝒏. Continued exploration of these pathways will enhance our understanding of CB2R modulation and its potential clinical applications. #cannabinoids #CNS #retrosynthesis #sidereactions

9

1 Kommentar

meet imSAVAR and SaxoCell Cluster at this interesting conference and learn more about new developments in cell and Gene therapies

8

🚀 We are thrilled to announce that Professor Dr. Judith Zaugg will now lead the 'Molecular and Computational Hematology-Immunology' group at the Department of Biomedicine in Basel. Judith Zaugg has been appointed as Professor of Molecular Medicine at the Universität Basel! Her groundbreaking research will focus on unraveling the molecular mechanisms behind hematological and immunological diseases, with an emphases on the interplay between cells and their microenvironment. With her team, Judith Zaugg will use high-throughput single-cell and spatial molecular profiling, combined with advanced computational techniques, to explore how genetic and chromatin-based modifications contribute to certain diseases. This pioneering work aims to identify new therapeutic targets and biomarkers to advance precision medicine in hematology and immunology. We look forward to the innovations and discoveries that will emerge from her new lab in Basel, enhancing diagnostic precision and patient care in these critical areas. 🔗 See the link in the comments for more information. #welcomeonboard #welcome #MolecularMedicine #Hematology #Immunology #PrecisionMedicine #TeamDBM

231

8 Kommentare

"Exciting breakthrough in medical research! Scientists from Shandong First Medical University & Shandong Academy of Medical Sciences, using Tsingke's oligo synthesis products, have successfully published a paper in Lancet Microbe. The study investigates an outbreak of severe pneumonia in Shandong, China, revealing the causative agent and human-to-human transmission of Chlamydia psittaci. This highlights the crucial role of research in understanding and combating infectious diseases. Learn more about our contributions to scientific advancements: https://www.tsingke.com/ Read here: https://lnkd.in/dtqEevdJ #Tsingke #TsingkeShowcase #Science #MedicalResearch

2

🚀 New Research Publication! 🚀 I’m excited to share our latest study just published in ACS Nano, which reveals a novel way to strengthen protein complexes, potentially revolutionizing cancer therapies. 🧬✨ In collaboration with Michael A. Nash and Byeongseon Yang from the University of Basel, we investigated the interaction between PD-L1 and a small scaffold protein known as Affibody. PD-L1 is crucial in allowing tumors to evade the immune system and has become a major target in cancer treatments. By enhancing the stability and strength of this protein complex, we demonstrated its potential as a more effective carrier for cancer-fighting drugs. Using advanced techniques, we made these complexes up to 4x stronger, significantly improving drug delivery systems. This research not only highlights our commitment to advancing healthcare through innovative science but also opens new avenues for optimizing bioconjugation strategies, potentially leading to more efficient and targeted therapies for various diseases. 📖 Read the full study: https://lnkd.in/eJ4atC7v #CancerResearch #PDL1 #Affibody #HealthcareInnovation #ProteinEngineering #Biotechnology

67

6 Kommentare